Mechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Richardson, Elizabeth ^a,b   Stockwell, Simon R ^a,b   Li, He ^b   Aherne, Wynne ^b   Cuomo, Maria Emanuela ^a,b   Mittnacht, Sibylle ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P21; PROTEIN P53; PROTEIN RB1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL ACTIVATION; CELL CYCLE PROGRESSION; CELL DAMAGE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE CHECKPOINT; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RADIOSENSITIVITY; RETINOBLASTOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL CYCLE; CELL CYCLE G1 PHASE; GENE EXPRESSION REGULATION; METABOLISM; REPORTER GENE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MAP KINASE KINASE 4; MODELS, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863230409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031627     Document Type: Article

References (84)

1. Dahele M, Senan S, (2010) Radiation oncology: overview and recent advances. J R Coll Physicians Edinb 40: 136-143; quiz 143-134.
2. Elshaikh M, Ljungman M, Ten Haken R, Lichter AS, (2006) Advances in radiation oncology. Annu Rev Med 57: 19-31.
3. Kim JJ, Tannock IF, (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-525.
4. Lindsay KJ, Coates PJ, Lorimore SA, Wright EG, (2007) The genetic basis of tissue responses to ionizing radiation. Br J Radiol 80 Spec No 1: S2-6.
5. Jorgensen TJ, (2009) Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 8: 665-670.
6. Kastan MB, Bartek J, (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-323.
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
8. Pauwels B, Wouters A, Peeters M, Vermorken JB, Lardon F, (2010) Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol 6: 1485-1496.
9. Kinsella TJ, (2009) Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics. Semin Oncol 36: S42-51.
10. Ward JF, (2000) Complexity of damage produced by ionizing radiation. Cold Spring Harb Symp Quant Biol 65: 377-382.
11. Khanna KK, Jackson SP, (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254.
12. Lukas J, Lukas C, Bartek J, (2004) Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 3: 997-1007.
13. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459.
14. Zhao H, Watkins JL, Piwnica-Worms H, (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 99: 14795-14800.
15. Chen MS, Ryan CE, Piwnica-Worms H, (2003) Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 23: 7488-7497.
16. Lavin MF, (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769.
17. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, et al. (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277: 1497-1501.
18. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, et al. (2003) Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2: 543-548.
19. Uto K, Inoue D, Shimuta K, Nakajo N, Sagata N, (2004) Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism. Embo J 23: 3386-3396.
20. Alderton GK, Galbiati L, Griffith E, Surinya KH, Neitzel H, et al. (2006) Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat Cell Biol 8: 725-733.
21. Reinhardt HC, Yaffe MB, (2009) Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 21: 245-255.
22. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, et al. (2010) DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell 40: 34-49.
23. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
24. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B, (2000) Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14: 1584-1588.
25. Burkhart DL, Sage J, (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671-682.
26. Assoian RK, Yung Y, (2008) A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer. Cell Cycle 7: 24-27.
27. Smith ML, Zhan Q, Bae I, Fornace AJ Jr, (1994) Role of retinoblastoma gene product in p53-mediated DNA damage response. Exp Cell Res 215: 386-389.
28. Haapajarvi T, Kivinen L, Pitkanen K, Laiho M, (1995) Cell cycle dependent effects of u.v.-radiation on p53 expression and retinoblastoma protein phosphorylation. Oncogene 11: 151-159.
29. Harrington EA, Bruce JL, Harlow E, Dyson N, (1998) pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci U S A 95: 11945-11950.
30. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, et al. (1994) p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A 91: 5320-5324.
31. Lanni JS, Jacks T, (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18: 1055-1064.
32. Deckbar D, Stiff T, Koch B, Reis C, Lobrich M, et al. The limitations of the G1-S checkpoint. Cancer Res 70: 4412-4421.
33. Agerbaek M, Alsner J, Marcussen N, Lundbeck F, von der Maase H, (2003) Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. Br J Cancer 89: 298-304.
34. Jahnson S, Risberg B, Karlsson MG, Westman G, Bergstrom R, et al. (1995) p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 28: 135-142.
35. Moonen L, Ong F, Gallee M, Verheij M, Horenblas S, et al. (2001) Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. nt J Radiat Oncol Biol Phys 49: 1305-1310.
36. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, et al. (1997) Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3: 1823-1829.
37. Broceno C, Wilkie S, Mittnacht S, (2002) RB activation defect in tumor cell lines. Proc Natl Acad Sci U S A 99: 14200-14205.
38. Dou QP, An B, Will PL, (1995) Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci U S A 92: 9019-9023.
39. Hitomi M, Yang K, Stacey AW, Stacey DW, (2008) Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol 28: 5478-5493.
40. Choo DW, Baek HJ, Motoyama N, Cho KH, Kim HS, et al. (2009) ATM is required for rapid degradation of cyclin D1 in response to gamma-irradiation. Biochem Biophys Res Commun 378: 847-850.
41. Di Leonardo A, Linke SP, Clarkin K, Wahl GM, (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551.
42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
43. Serrano M, Hannon GJ, Beach D, (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
44. Hall M, Bates S, Peters G, (1995) Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581-1588.
45. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
46. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, et al. (1999) Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A 96: 1002-1007.
47. Gu J, Xia X, Yan P, Liu H, Podust VN, et al. (2004) Cell cycle-dependent regulation of a human DNA helicase that localizes in DNA damage foci. Mol Biol Cell 15: 3320-3332.
48. Zhou BB, Bartek J, (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4: 216-225.
49. Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, et al. (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119: 2784-2794.
50. Petersen L, Hasvold G, Lukas J, Bartek J, Syljuasen RG, (2010) p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors. Cell Prolif 43: 365-371.
51. Warmerdam DO, Kanaar R, (2010) Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat Res 704: 2-11.
52. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, et al. (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-1909.
53. Claudio PP, Tonini T, Giordano A, (2002) The retinoblastoma family: twins or distant cousins? Genome Biol 3: reviews3012.
54. Stewart ZA, Pietenpol JA, (2001) p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 14: 243-263.
55. Zhang X, Succi J, Feng Z, Prithivirajsingh S, Story MD, et al. (2004) Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol 24: 9207-9220.
56. Knudsen ES, Sexton CR, Mayhew CN, (2006) Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr Mol Med 6: 749-757.
57. Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, et al. (2001) Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem 276: 44003-44011.
58. Brooks CL, Gu W, (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
59. Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res 70: 6325-6335.
60. Lin Y, Khokhlatchev A, Figeys D, Avruch J, (2002) Death-associated protein 4 binds MST1 and augments MST1-induced apoptosis. J Biol Chem 277: 47991-48001.
61. Glantschnig H, Rodan GA, Reszka AA, (2002) Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem 277: 42987-42996.
62. Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA, (2001) Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J Biol Chem 276: 14909-14915.
63. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, et al. (2001) Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 21: 2743-2754.
64. Fuchs SY, Adler V, Pincus MR, Ronai Z, (1998) MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A 95: 10541-10546.
65. Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez-Capetillo O, et al. (2009) p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol 29: 4341-4351.
66. Densham RM, O'Neill E, Munro J, Konig I, Anderson K, et al. (2009) MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol 29: 6380-6390.
67. Chehab NH, Malikzay A, Appel M, Halazonetis TD, (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14: 278-288.
68. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C, (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289-300.
69. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, et al. (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824-1827.
70. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, et al. (1992) Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71: 323-334.
71. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, et al. (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493-504.
72. Ludlow JW, Howell RL, Smith HC, (1993) Hypoxic stress induces reversible hypophosphorylation of pRB and reduction in cyclin A abundance independent of cell cycle progression. Oncogene 8: 331-339.
73. Fasanaro P, Magenta A, Zaccagnini G, Cicchillitti L, Fucile S, et al. (2006) Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress. Faseb J 20: 1242-1244.
74. Tomida A, Suzuki H, Kim HD, Tsuruo T, (1996) Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene 13: 2699-2705.
75. Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, et al. (2000) Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 275: 35091-35097.
76. Veech RL, (2003) A humble hexose monophosphate pathway metabolite regulates short- and long-term control of lipogenesis. Proc Natl Acad Sci U S A 100: 5578-5580.
77. Kalia VK, Prabhakara S, Narayanan V, (2009) Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy. J Cancer Res Ther 5 (Suppl 1): S57-60.
78. Tschoep K, Conery AR, Litovchick L, DeCaprio JA, Settleman J, et al. (2011) A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev 25: 814-830.
79. Niida H, Nakanishi M, (2006) DNA damage checkpoints in mammals. Mutagenesis 21: 3-9.
80. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB, (2009) Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8: 3112-3119.
81. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
82. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
83. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
84. Swanton C, Nicke B, Marani M, Kelly G, Downward J, (2007) Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs. Cell Cycle 6: 2001-2004.